tmcnet.com
May 20, 2008
Flemington, N.J.-based NovaDel plans to use the money to "reinitiate a lot of our clinical development" that had been curtailed due to a lack of money, Mike Spicer, chief financial officer, told BioWorld Today. Under the deal, Paris-based BioAlliance will be responsible for European regulatory...
[read full story]